Business:
Antibody Immunotherapy
Drug notes:
PYX-106 Clin0 cancers; 3 add'l programs tumors
About:
Pyxis Oncology is developing therapies for difficult-to-treat cancers. To tackle cancer, Pyxis is pursuing both antibody-drug conjugates (ADCs) and monoclonal antibodies (mAb) to build an arsenal of next-generation therapeutics. ADCs work by targeting tumors and releasing cytotoxic payloads, while mAbs work to modulate immune regulatory mechanisms to serve as immunotherapies.. Pyxis has assembled a portfolio of clinical assets for both these classes. This includes their ADC, PYX-201, an ADC in Phase 1 clinical trials in patients with relapsed or refractory solid tumors.